On the ARDS trial, in my stats I was working off a 10% target improvement, which is reasonably easy to meet. While this does leave some room for post-hoc analysis on secondary endpoints to show some real promise, I think they should have published a few more details about the trial and what threshold they were trying to achieve. I was also under the impression that the Bayesian endpoints were only in use for the interim analyses - so much of the trial design was not public, so the shock of what they were actually going for was a big one for me. However...
If covid reinfection is possible (seems likely) and there is some promise in the full trial data, then the next phase 3 trial could be for "all cause ARDS" (ie. including covid) targeting patients a little earlier in the process and with guidance on trial design from novartis. There's a chance the cells don't work reliably enough and in a consistent way that they will be able to pass a clinical trial... but honestly the ARDS trial was so hastily put together and not safeguarded against the changing nature of the virus, that there's a 50% chance it's bad/unfortunate trial design and a 50% chance it's the product. If I am novartis, I might just buy mesoblast in entirety for a broad offer of something like $3.50 a share and take the tech forwards myself, rather than dicking around with any milestone payments. If not, then I expect them to be heavily involved in constructing the trial design and using an endpoint that can be met for approval from the FDA or in Europe.
- Forums
- ASX - By Stock
- MSB
- USD573M in retained losses and a less than great 2020!. 2021 a year that cannot get worse
USD573M in retained losses and a less than great 2020!. 2021 a year that cannot get worse, page-2
-
- There are more pages in this discussion • 310 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B |
Open | High | Low | Value | Volume |
$1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 8683 | $1.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.17 | 32999 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 8683 | 1.155 |
7 | 295447 | 1.150 |
3 | 70786 | 1.145 |
6 | 196386 | 1.140 |
3 | 75486 | 1.135 |
Price($) | Vol. | No. |
---|---|---|
1.165 | 32999 | 1 |
1.170 | 62618 | 6 |
1.175 | 48590 | 3 |
1.180 | 79079 | 4 |
1.185 | 17090 | 2 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online